The S&P 500 saw major movements with Palantir and Moderna stocks rising sharply, while Lululemon faced a significant decline in share value. Analysts weigh in on Tesla and Broadcom's performance amid market shifts.
In a groundbreaking move, the FDA has approved Moderna's lower-dose Covid-19 vaccine for older adults and at-risk individuals. Get ready for a new option this fall as Moderna targets the LP.8.1 variant!
Robert F. Kennedy Jr. canceled a critical $766 million contract with Moderna for a bird flu vaccine, raising concerns about public health and vaccine safety amidst a potential outbreak.
The U.S. government has canceled a crucial $770 million contract with Moderna for an avian flu vaccine, risking public health as pandemics prove to be a costly threat. Experts warn of the implications of prioritizing military spending over health security.
The U.S. has approved Moderna's new COVID-19 vaccine, mNexspike, specifically for high-risk groups. This innovative option offers a lower dose while maintaining effectiveness, marking a pivotal step in the fight against coronavirus.
In a surprising move, the HHS has terminated a $590 million contract with Moderna for H5 avian influenza vaccine development, raising alarms among health experts amidst rising H5N1 threats.
In a surprising move, the Department of Health and Human Services has withdrawn millions in funding for Moderna's bird flu vaccine development, raising concerns about the nation's pandemic preparedness amid ongoing tensions over vaccine safety.
Moderna's combined Covid and flu vaccine has outperformed traditional shots in a recent phase 3 trial, generating higher antibody levels and showing promise for dual protection against both viruses.
